0001080014
false
0001080014
2023-11-01
2023-11-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): November 1, 2023
INNOVIVA, INC.
(Exact Name of Registrant as Specified in its
Charter)
Delaware |
000-30319 |
94-3265960 |
(State or Other Jurisdiction of
Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification
Number) |
1350 Old Bayshore Highway,
Suite
400
Burlingame, California 94010
(650) 238-9600
(Addresses, including zip code, and telephone
numbers, including area code, of principal executive offices)
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, par value $0.01 per share |
|
INVA |
|
The NASDAQ Global Select Market |
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition
On November 1, 2023, Innoviva, Inc. (the “Company”)
issued a press release regarding its results of operations and financial condition for the quarter ended September 30, 2023. A copy
of the press release is furnished as Exhibit 99.1 to this Current Report.
The information in Item 2.02 of this Current Report on Form 8-K,
including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
Date: November 1, 2023 |
By: |
/s/ Pavel Raifeld |
|
|
Pavel Raifeld |
|
|
Chief Executive Officer |
Exhibit 99.1
Innoviva Reports
Third Quarter 2023 Financial Results and Highlights Recent Company Progress
Received GSK
royalties of $57.0 million and net product revenues of $13.7 million in the third quarter of 2023
Launched
first-in-class therapy XACDURO® for treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial
pneumonia caused by susceptible strains of Acinetobacter
Announced positive topline Phase 3 zoliflodacin
data for treatment of gonorrhea in November 2023
Repurchased $11.0
million of common stock
BURLINGAME,
Calif. – November 1, 2023 – Innoviva, Inc. (NASDAQ: INVA) (“Innoviva”
or the “Company”), a diversified holding company with a portfolio of royalties and
other healthcare assets, today reported financial results for the third quarter ended September 30, 2023, highlighted select
corporate achievements and provided an overview of its key business initiatives.
·
Gross royalty revenue from Glaxo Group Limited (“GSK”) for the third quarter 2023 was $57.0 million, which included royalties
of $45.6 million from global net sales of RELVAR®/BREO® ELLIPTA® and royalties of $11.4
million from global net sales of ANORO® ELLIPTA® compared to $65.6 million for the third quarter of 2022,
which included royalties of $55.7
million from global net sales of RELVAR®/BREO® ELLIPTA®
and $9.9 million from global net sales of ANORO® ELLIPTA®,
respectively.
·
Net product sales and license revenue for the third quarter of 2023 was $13.7 million, which included $8.0 million from GIAPREZA®
net sales, $5.1 million from XERAVA® net sales and $0.6 million from XACDURO® net sales.
·
Net income was $82.0 million, or $1.26 basic per share, for the third quarter of 2023, compared to net income of $265.5 million, or $3.81
basic per share, for the third quarter of 2022; the decrease was primarily driven by non-repeated gain on sales of our subsidiary, Theravance
Respiratory Company, and its TRELEGY® ELLIPTA® royalty stream in July 2022.
·
Cash and cash equivalents totaled $180.0 million. Royalty, product sales and milestone receivables totaled $67.8 million
as of September 30, 2023.
"The third quarter of 2023 was marked by significant revenues
stemming from our royalty portfolio and solid performance by our internal product portfolio,” said Pavel Raifeld, Chief Executive
Officer of Innoviva. “A few weeks ago, we launched XACDURO® in the United States and are encouraged by the market receptivity.
Moreover, we announced positive topline data from the Phase 3 trial of our lead pipeline asset, zoliflodacin, and are excited about its
potential to affect the treatment paradigm for gonorrhea patients, especially in the presence of antimicrobial resistance concerns. These
milestones reinforce the strength and promise of our infectious disease and critical care business.”
Mr. Raifeld concluded, “We continued to exercise cost discipline
and saw meaningful operational progress among our investees. In addition, we benefited from significant increases in the equity fair
values of our investments. We are confident in the prospects of our business and plan to continue to pursue shareholder-friendly policies,
such as share repurchases.”
Third
Quarter 2023 and Recent Highlights
GSK
Net Sales
| · | Third
quarter 2023 net sales of RELVAR®/BREO® ELLIPTA®
by GSK were $303.9 million with $109.5 million in net sales from the U.S. market and $194.4
million from non-U.S. markets. |
| · | Third
quarter 2023 net sales of ANORO® ELLIPTA® by GSK were $175.8
million with $89.2 million net sales from the U.S. market and $86.6 million from non-U.S.
markets. |
Corporate
Updates
| · | During
the third quarter of 2023, Innoviva repurchased 856,750 shares of its outstanding common
stock for $11.0 million. |
| · | On
July 10, 2023, Innoviva’s wholly owned subsidiary, Innoviva Strategic
Opportunities, entered into a credit and security agreement with Armata Pharmaceuticals, Inc.
(NYSE: ARMP) (“Armata”) and invested $25.0 million to advance Armata’s
pipeline of therapeutic phage candidates and support the buildout of its state-of-the art
cGMP manufacturing facility. |
| · | On
August 21, 2023, Innoviva appointed Stephen Basso as Chief Financial Officer. |
Clinical
Updates
| · | In
September 2023, Innoviva’s wholly owned subsidiary, Innoviva Specialty
Therapeutics, launched XACDURO® (sulbactam for injection; durlobactam for
injection), co-packaged for intravenous use in patients 18 years of age and older for the
treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia
(HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex
(Acinetobacter). XACDURO® is the first and only pathogen-targeted antibiotic
and a significant advancement in the way healthcare professionals treat Acinetobacter. |
| · | In November 2023, in collaboration with The Global Antibiotic Research & Development Partnership (GARDP), we announced that zoliflodacin,
a first-in-class antibiotic, met its primary endpoint in a global pivotal phase 3 clinical trial for the treatment of uncomplicated gonorrhea,
a prevalent disease affecting over 80 million patients a year globally with rapidly rising antimicrobial resistance concerns. Study investigators
found that oral zoliflodacin demonstrated statistical non-inferiority of microbiological cure at the urogenital site when compared to
treatment with intramuscular injection of ceftriaxone and oral azithromycin, a current global standard of care regimen. In
the study, zoliflodacin demonstrated a favorable safety profile and was generally well tolerated, with the majority of adverse events
being mild-to-moderate. There were no discontinuations reported due to adverse events, serious adverse events, or deaths. |
About
Innoviva
Innoviva is a diversified
holding company with a portfolio of royalties and other healthcare assets. Innoviva’s royalty portfolio includes respiratory assets
partnered with Glaxo Group Limited (“GSK”), including RELVAR®/BREO® ELLIPTA® (fluticasone
furoate/ vilanterol, “FF/VI”) and ANORO® ELLIPTA® (umeclidinium bromide/ vilanterol, “UMEC/VI”).
Under the Long-Acting Beta2 Agonist (“LABA”) Collaboration Agreement, Innoviva is entitled to receive royalties from
GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®.
Innoviva’s other innovative healthcare assets include infectious disease and hospital assets stemming from acquisitions of Entasis
Therapeutics, including XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use
approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused
by susceptible strains of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter) and the investigational zoliflodacin
currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA®
(angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA®
(eravacycline) for the treatment of complicated intra-abdominal infections in adults.
ANORO®,
RELVAR® and BREO® are trademarks of the GSK group of companies.
Forward
Looking Statements
This
press release contains certain “forward-looking” statements as that term is defined in the Private Securities Litigation
Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, and future events. Innoviva intends
such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E
of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. The words “anticipate”,
“expect”, “goal”, “intend”, “objective”, “opportunity”, “plan”,
“potential”, “target” and similar expressions are intended to identify such forward-looking statements. Such
forward-looking statements involve substantial risks, uncertainties, and assumptions. These statements are based on the current estimates
and assumptions of the management of Innoviva as of the date of this press release and are subject to known and unknown risks, uncertainties,
changes in circumstances, assumptions and other factors that may cause the actual results of Innoviva to be materially different from
those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those
indicated by such forward-looking statements include, among others, risks related to: expected cost savings; lower than expected future
royalty revenue from respiratory products partnered with GSK; the commercialization of RELVAR®/BREO® ELLIPTA®,
ANORO® ELLIPTA®, GIAPREZA®, XERAVA® and XACDURO® in
the jurisdictions in which these products have been approved; the strategies, plans and objectives of Innoviva (including Innoviva’s
growth strategy and corporate development initiatives); the timing, manner, and amount of potential capital returns to shareholders;
the status and timing of clinical studies, data analysis and communication of results; the potential benefits and mechanisms of action
of product candidates; expectations for product candidates through development and commercialization; the timing of regulatory approval
of product candidates; and projections of revenue, expenses and other financial items; the impact of the novel coronavirus (“COVID-19”);
the timing, manner and amount of capital deployment, including potential capital returns to stockholders; and risks related to the Company’s
growth strategy. Other risks affecting Innoviva are described under the headings “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” contained in Innoviva’s Annual Report on Form 10-K
for the year ended December 31, 2022 and Quarterly Reports on Form 10-Q, which are on file with the Securities and Exchange
Commission (“SEC”) and available on the SEC’s website at www.sec.gov. Past performance is not necessarily indicative
of future results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given
these uncertainties, you should not place undue reliance on these forward-looking statements. The information in this press release is
provided only as of the date hereof, and Innoviva assumes no obligation to update its forward-looking statements on account of new information,
future events or otherwise, except as required by law.
INNOVIVA,
INC.
Condensed
Consolidated Statements of Income
(in
thousands, except per share data)
(Unaudited)
| |
Three Months Ended | | |
Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Revenue: | |
| | | |
| | | |
| | | |
| | |
Royalty revenue, net (1) | |
$ | 53,558 | | |
$ | 62,150 | | |
$ | 172,681 | | |
$ | 260,429 | |
Net product sales | |
| 13,701 | | |
| 5,107 | | |
| 40,942 | | |
| 5,107 | |
License revenue | |
| - | | |
| - | | |
| 11,000 | | |
| - | |
Total revenue | |
| 67,259 | | |
| 67,257 | | |
| 224,623 | | |
| 265,536 | |
Expenses: | |
| | | |
| | | |
| | | |
| | |
Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding depreciation and amortization of intangible assets) | |
| 10,182 | | |
| 3,680 | | |
| 27,910 | | |
| 3,680 | |
Cost of license revenue | |
| - | | |
| - | | |
| 1,600 | | |
| - | |
Selling, general and administrative | |
| 28,636 | | |
| 27,810 | | |
| 71,913 | | |
| 46,084 | |
Research and development | |
| 3,989 | | |
| 11,725 | | |
| 31,566 | | |
| 31,447 | |
Amortization of acquired intangible assets | |
| 6,511 | | |
| 1,511 | | |
| 15,274 | | |
| 1,511 | |
Gain on sale of Theravance Respiratory Company, LLC (“TRC”) | |
| - | | |
| (266,696 | ) | |
| - | | |
| (266,696 | ) |
Loss on debt extinguishment | |
| - | | |
| - | | |
| - | | |
| 20,662 | |
Changes in fair values of equity method investments, net | |
| (71,980 | ) | |
| (10,298 | ) | |
| (67,886 | ) | |
| 44,475 | |
Changes in fair values of equity and long-term investments, net | |
| 2,640 | | |
| 10,168 | | |
| 4,887 | | |
| 23,406 | |
Interest and dividend income | |
| (4,114 | ) | |
| (2,135 | ) | |
| (11,032 | ) | |
| (3,181 | ) |
Interest expense | |
| 4,396 | | |
| 5,096 | | |
| 13,205 | | |
| 11,761 | |
Other expense, net | |
| 1,047 | | |
| (28 | ) | |
| 4,289 | | |
| 750 | |
Total expenses | |
| (18,693 | ) | |
| (219,167 | ) | |
| 91,726 | | |
| (86,101 | ) |
Income before income taxes | |
| 85,952 | | |
| 286,424 | | |
| 132,897 | | |
| 351,637 | |
Income tax expense | |
| 3,906 | | |
| 57,077 | | |
| 14,706 | | |
| 63,061 | |
Net income | |
| 82,046 | | |
| 229,347 | | |
| 118,191 | | |
| 288,576 | |
Net income attributable to noncontrolling interest | |
| - | | |
| (36,176 | ) | |
| - | | |
| 6,341 | |
Net income attributable to Innoviva stockholders | |
$ | 82,046 | | |
$ | 265,523 | | |
$ | 118,191 | | |
$ | 282,235 | |
| |
| | | |
| | | |
| | | |
| | |
Basic net income per share attributable to Innoviva stockholders | |
$ | 1.26 | | |
$ | 3.81 | | |
$ | 1.79 | | |
$ | 4.05 | |
Diluted net income per share attributable to Innoviva stockholders | |
$ | 0.98 | | |
$ | 2.80 | | |
$ | 1.45 | | |
$ | 3.07 | |
| |
| | | |
| | | |
| | | |
| | |
Shares used to compute basic net income per share | |
| 64,953 | | |
| 69,731 | | |
| 66,016 | | |
| 69,640 | |
Shares used to compute diluted net income per share | |
| 86,164 | | |
| 95,830 | | |
| 87,504 | | |
| 95,072 | |
(1)
Total net revenue is comprised of the following (in thousands):
| |
Three Months Ended | | |
Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
(unaudited) | | |
(unaudited) | |
Royalties | |
$ | 57,014 | | |
$ | 65,606 | | |
$ | 183,049 | | |
$ | 270,797 | |
Amortization of capitalized fees | |
| (3,456 | ) | |
| (3,456 | ) | |
| (10,368 | ) | |
| (10,368 | ) |
Royalty revenue, net | |
$ | 53,558 | | |
$ | 62,150 | | |
$ | 172,681 | | |
$ | 260,429 | |
INNOVIVA,
INC.
Condensed
Consolidated Balance Sheets
(in
thousands)
(unaudited)
| |
September 30, | | |
December 31, | |
| |
2023 | | |
2022 | |
Assets | |
| | |
| |
Cash and cash equivalents | |
$ | 179,997 | | |
$ | 291,049 | |
Royalty and product sale receivables | |
| 67,765 | | |
| 64,073 | |
Inventory, net | |
| 40,515 | | |
| 55,897 | |
Prepaid expense and other current assets | |
| 16,722 | | |
| 32,492 | |
Property and equipment, net | |
| 361 | | |
| 170 | |
Equity and long-term investments | |
| 529,531 | | |
| 403,013 | |
Capitalized fees | |
| 87,239 | | |
| 97,607 | |
Right-of-use assets | |
| 2,828 | | |
| 3,265 | |
Goodwill | |
| 17,905 | | |
| 26,713 | |
Intangible assets | |
| 236,845 | | |
| 252,919 | |
Deferred tax assets | |
| 4,952 | | |
| - | |
Other assets | |
| 3,444 | | |
| 4,299 | |
Total assets | |
$ | 1,188,104 | | |
$ | 1,231,497 | |
| |
| | | |
| | |
Liabilities and stockholders’ equity | |
| | | |
| | |
Other current liabilities | |
$ | 33,802 | | |
$ | 32,322 | |
Accrued interest payable | |
| 833 | | |
| 4,359 | |
Deferred revenue | |
| 1,548 | | |
| 2,094 | |
Convertible subordinated notes, due 2023, net | |
| - | | |
| 96,193 | |
Convertible senior notes, due 2025, net | |
| 191,115 | | |
| 190,583 | |
Convertible senior notes, due 2028, net | |
| 254,603 | | |
| 253,597 | |
Other long term liabilities | |
| 68,690 | | |
| 70,918 | |
Deferred tax liabilities | |
| - | | |
| 5,771 | |
Income tax payable - long term | |
| 10,020 | | |
| 9,872 | |
Innoviva stockholders’ equity | |
| 627,493 | | |
| 565,788 | |
Total liabilities and stockholders’ equity | |
$ | 1,188,104 | | |
$ | 1,231,497 | |
INNOVIVA,
INC.
Cash
Flows Summary
(in thousands)
(unaudited)
| |
Nine Months
Ended September 30, | |
| |
2023 | | |
2022 | |
Net cash provided by operating activities | |
$ | 107,808 | | |
$ | 192,827 | |
Net cash used in investing activities | |
| (61,610 | ) | |
| (47,956 | ) |
Net cash used in financing activities | |
| (157,250 | ) | |
| (45,567 | ) |
Net change | |
$ | (111,052 | ) | |
$ | 99,304 | |
Cash and cash equivalents at beginning
of period | |
| 291,049 | | |
| 201,525 | |
Cash, cash equivalents and restricted
cash at end of period | |
$ | 179,997 | | |
$ | 300,829 | |
Investors
and Media Contact:
Argot Partners
(212) 600-1902
innoviva@argotpartners.com
v3.23.3
Cover
|
Nov. 01, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Nov. 01, 2023
|
Entity File Number |
000-30319
|
Entity Registrant Name |
INNOVIVA, INC.
|
Entity Central Index Key |
0001080014
|
Entity Tax Identification Number |
94-3265960
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
1350 Old Bayshore Highway
|
Entity Address, Address Line Two |
Suite
400
|
Entity Address, City or Town |
Burlingame
|
Entity Address, State or Province |
CA
|
Entity Address, Postal Zip Code |
94010
|
City Area Code |
650
|
Local Phone Number |
238-9600
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, par value $0.01 per share
|
Trading Symbol |
INVA
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Innoviva (NASDAQ:INVA)
Historical Stock Chart
From Jul 2024 to Aug 2024
Innoviva (NASDAQ:INVA)
Historical Stock Chart
From Aug 2023 to Aug 2024